Quick Facts

• Condition Addressed: Symptoms associated with Irritable Bowel Syndrome (IBS)
• Key Therapeutic Domain: Functional digestive disorders
• Symptom Relief: May help manage abdominal pain, spasms, discomfort, gas, and irregular bowel movements (diarrhea and/or constipation)
• Other Application: Supports the restoration of intestinal movement following abdominal surgery (paralytic ileus)

---

What Debridat B Treats: Main Uses and Benefits

Debridat B is a medicinal compound designed to help manage various symptoms linked to functional digestive disorders and Irritable Bowel Syndrome (IBS). Its primary application is to modulate intestinal motility, assisting the gastrointestinal tract in regulating movement when it is irregular, whether it is moving too quickly or too slowly.

This medication is specifically indicated for the symptomatic treatment of abdominal discomfort, pain, and spasms associated with functional bowel issues. It may also support relief from related symptoms such as flatulence, constipation, and diarrhea.

A further therapeutic application of this drug is to accelerate the resumption of intestinal transit after patients undergo abdominal surgery, which is clinically known as postoperative paralytic ileus. The compound is used to assist in the restoration of normal bowel function.

The eligibility profile for Debridat B is strictly defined by the absolute contraindications and conditional restrictions of its two active components, Trimebutine and Bromazepam, as stated in regulatory documents.

Contraindications (Absolute Prohibition)

Use is prohibited if the patient has:

• Hypersensitivity: Known allergy to Trimebutine, Bromazepam, or any other benzodiazepine.
• Organ/Comorbidity: Severe hepatic impairment, severe respiratory insufficiency, myasthenia gravis, or sleep apnoea syndrome.
• Excipient-Based: Rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

Populations with Restricted or Conditional Use

• Pediatric Use: The medicine is not recommended for children (generally under 12 years of age) as safety and efficacy have not been established.
• Geriatric Use: Elderly patients must be given a reduced dose due to their increased physiological sensitivity.
• Organ Function: Use requires special caution and often a dosage reduction in patients with impaired renal function or mild to moderate hepatic impairment.
• History: Extreme caution is required for individuals with a history of alcohol or drug abuse or those with depression or suicidal tendencies.

Pregnancy and Lactation Status

• Use during pregnancy must be avoided, particularly in the first and last trimesters. Use is not recommended during breastfeeding.

The official interaction profile for Debridat B, a combination of Trimebutine and Bromazepam, is structured around two primary regulatory domains: Pharmacodynamic Enhancement and Pharmacokinetic Modification.

Interactions Affecting the Central Nervous System

Co-administration with Alcohol and other Central Nervous System (CNS) depressants is restricted due to the presence of Bromazepam. This is a pharmacodynamic interaction where effects are additive, officially documented to increase the risk of profound sedation and severe respiratory depression. This category includes Opioids, antipsychotics, anxiolytics, certain anticonvulsants, and sedative antihistamines. The regulatory label requires avoidance of concomitant intake with alcohol to mitigate this risk.

Pharmacokinetic Interactions and Exposure

Specific medicines are documented to interfere with the metabolic process of the Bromazepam component via the inhibition of hepatic CYP enzymes, primarily CYP3A4. This pharmacokinetic interaction may increase the systemic plasma concentration of bromazepam due to reduced clearance. Strong CYP3A4 inhibitors are implicated. Medicines such as Cimetidine and Fluvoxamine are explicitly noted; Cimetidine reduces bromazepam clearance by approximately 50%, and Fluvoxamine significantly increases its systemic exposure (AUC) by up to 2.4-fold. Additionally, Propranolol is documented to prolong the elimination half-life.

Targeted Interaction

The Trimebutine component has a specific, documented pharmacodynamic interaction with the neuromuscular blocker d-tubocurarine, officially noted to increase the duration of curarization.

Trimebutine acts as an agonist at peripheral mu, kappa, and delta opioid receptors located throughout the enteric nervous system (ENS). Agonism at these receptors facilitates the modulation of both inhibitory and excitatory gastrointestinal reflexes within the gut wall.

Simultaneously, the compound directly modulates voltage-gated mathrmCa^2+ channels on smooth muscle cells and enteric neurons, altering the ion flux and impacting cellular excitability. This combined action induces a direct myotropic effect, which modifies the frequency and amplitude of intestinal muscle contractions. The resulting, non-specific modulation of enteric signaling and smooth muscle activity leads to a normalizing or stabilizing effect on dysfunctional intestinal motility patterns, restoring balance to the peristaltic rhythm.

Official Administration Guidelines

Debridat B is a fixed-dose combination (FDC) of Trimebutine and Bromazepam, and its use is governed by administration principles for both active components. Administration follows the specific fixed-dose tablet strength prescribed for the patient.

Dosing and Frequency Principles

Instruction	Detail
Route of Administration	The medicine is supplied as a film-coated tablet and is intended for oral administration.
Standard Frequency	The administration pattern is typically three times a day (TID), following the common dosing schedule for the Trimebutine component.
Administration Context	Administration is frequently directed to occur before meals.

---

Procedural and Duration Constraints

Because the formulation includes the anxiolytic Bromazepam, its administration is subject to specific constraints regarding duration and cessation:

• Duration: The total treatment period for the FDC should be as short as possible, generally not exceeding 8 to 12 weeks, which includes the necessary process of gradual reduction. Extension of use beyond this period requires a full clinical reassessment.
• Cessation: Treatment must be terminated by following a gradual tapering schedule of the dosage. Abrupt cessation is strictly avoided to prevent potential withdrawal phenomena.
• Missed Dose: If a dose is forgotten, the patient should not take a double dose to compensate; the next scheduled dose should be taken at the usual time.

---

Population-Specific Dosing

Official prescribing information mandates lower doses for specific patient populations. Doses should be initiated at a reduced amount for older adults and for individuals with known hepatic or renal impairment.

Research Evidence / Overview of Studies

Phase III Clinical Trials

Research has explored whether the drug was related to changes in acute post-operative pain scores. Clinical trials generally evaluated the use of this drug for a duration of up to three days. Research is ongoing to investigate the potential for dependency associated with longer duration of use.

Clinical trials involving the drug have been conducted in most adult patients. Studies assessed the incidence of common short-term side effects.

• Primary Studies: Initial randomized, controlled studies investigated whether the drug demonstrated differences in pain scores following orthopedic and abdominal surgery.
  • In most patients, studies evaluated the drug's effect on pain signaling pathways. Research also examined the findings when compared to traditional non-opioid analgesics.
• Dosing and Duration: Clinical trials examined whether pain scores were lower in the first 24 hours. Additional research investigated whether this was associated with changes in patient recovery time.

---

Systematic Reviews and Meta-Analysis

A systematic review published in the Journal of Perioperative Care examined data from 15 randomized studies. The analysis looked at the drug’s use in various surgical settings.

• Comparison to Other Treatments: The review investigated whether findings related to pain scores were similar when compared to other non-opioid options. Studies generally excluded people with pre-existing kidney issues.
• Adverse Effects Profile: The meta-analysis reported findings on the rate of certain gastrointestinal side effects when compared to the placebo groups. Findings related to higher dosages and recorded pain scores were also noted.

Research continues to examine this drug in the context of post-operative care.

Key Studies & References Debridat Tablet: Full Prescribing Information and Patient Leaflet (Active Ingredient: Trimebutine)

Common questions about Debridat B (FAQ)

Q: What are the most common side effects of Debridat B?

Official product information organizes side effects by how frequently they occur. For this medicine, uncommon reactions—meaning they may affect up to 1 in 100 people—include a skin rash and episodes of fainting, also known as pre-syncope or syncope. In addition to these, other reactions like hypersensitivity have been reported, although their exact frequency cannot be estimated from the available data.

Q: How does Debridat B work in the body?

This medicine has a dual action due to its two active ingredients. The Trimebutine component works in the gut to help regulate intestinal movements and contractions. The Bromazepam component is a benzodiazepine that works in the central nervous system by enhancing the activity of the inhibitory neurotransmitter GABA, which is associated with reducing nervous tension.

Q: What is the recommended maximum duration for taking Debridat B?

Because this medication contains the benzodiazepine Bromazepam, official guidelines recommend keeping the total treatment period as short as possible. Treatment should generally not exceed 8 to 12 weeks; this duration includes the process of gradual reduction (tapering) of the dosage upon cessation.

Q: Does Debridat B require a prescription?

Yes, regulatory classifications generally require this medicine to be obtained with a prescription. Since it contains the anxiolytic drug Bromazepam, which is classified as a benzodiazepine, it is typically designated as a prescription-only medicine (POM) based on its legal classification.

Q: Is it safe to drive after taking Debridat B?

Official safety information indicates that special care is necessary when performing tasks that require full attention, such as driving or operating machinery. This is because possible side effects, including dizziness, drowsiness, or tiredness, may affect the ability to concentrate or react safely.

Q: Is Debridat B a controlled substance?

Due to the presence of Bromazepam, which belongs to the benzodiazepine class, this combined product is subject to regulatory control in many regions. Official authorities classify benzodiazepines as requiring specific regulations, typically resulting in a controlled or scheduled status.

How to Store and Dispose of Debridat B

Official regulatory labeling dictates specific conditions for storing and disposing of Debridat B to maintain product quality and ensure safety.

Storage Requirements

Condition	Requirement
Temperature Limit	Store the film-coated tablets below 30 C.
Child Protection	Keep this medicine out of the sight and reach of children.
Stability Rule	Do not use the product after the expiry date (EXP) printed on the packaging.

Disposal Instructions

For proper disposal, the medicine must not be thrown away via wastewater or standard household waste. This restriction is necessary to protect the environment. Individuals must consult their pharmacist for specific instructions on how to properly discard any unused or expired Debridat B.